Free Trial
NASDAQ:NBIX

Neurocrine Biosciences (NBIX) Stock Price, News & Analysis

Neurocrine Biosciences logo
$138.49 +0.36 (+0.26%)
As of 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Neurocrine Biosciences Stock (NASDAQ:NBIX)

Key Stats

Today's Range
$137.00
$138.94
50-Day Range
$123.98
$138.13
52-Week Range
$84.23
$154.61
Volume
203,599 shs
Average Volume
1.24 million shs
Market Capitalization
$13.74 billion
P/E Ratio
41.02
Dividend Yield
N/A
Price Target
$159.50
Consensus Rating
Moderate Buy

Company Overview

Neurocrine Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
98th Percentile Overall Score

NBIX MarketRank™: 

Neurocrine Biosciences scored higher than 98% of companies evaluated by MarketBeat, and ranked 39th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Neurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 18 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Neurocrine Biosciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Neurocrine Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Neurocrine Biosciences are expected to grow by 51.17% in the coming year, from $4.28 to $6.47 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Neurocrine Biosciences is 40.86, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.52.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Neurocrine Biosciences is 40.86, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.80.

  • Price to Earnings Growth Ratio

    Neurocrine Biosciences has a PEG Ratio of 0.99. PEG Ratios around 1 indicate that a company is correctly valued.

  • Price to Book Value per Share Ratio

    Neurocrine Biosciences has a P/B Ratio of 5.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Neurocrine Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    3.02% of the float of Neurocrine Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Neurocrine Biosciences has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Neurocrine Biosciences has recently decreased by 11.76%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Neurocrine Biosciences does not currently pay a dividend.

  • Dividend Growth

    Neurocrine Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.02% of the float of Neurocrine Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Neurocrine Biosciences has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Neurocrine Biosciences has recently decreased by 11.76%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Neurocrine Biosciences has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 21 news articles for Neurocrine Biosciences this week, compared to 18 articles on an average week.
  • Search Interest

    10 people have searched for NBIX on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,955,553.00 in company stock.

  • Percentage Held by Insiders

    Only 4.80% of the stock of Neurocrine Biosciences is held by insiders.

  • Percentage Held by Institutions

    92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Neurocrine Biosciences' insider trading history.
Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NBIX Stock News Headlines

How “Trump’s New Dollar” Could Impact Your Wealth
President Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best."tc pixel
Neurocrine Biosciences’ Earnings Call Highlights Growth
See More Headlines

NBIX Stock Analysis - Frequently Asked Questions

Neurocrine Biosciences' stock was trading at $136.50 at the beginning of 2025. Since then, NBIX stock has increased by 1.0% and is now trading at $137.8850.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its earnings results on Wednesday, July, 30th. The company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.98 by $0.08. The firm's quarterly revenue was up 16.5% on a year-over-year basis.
Read the conference call transcript
.

Neurocrine Biosciences' board authorized a stock buyback program on Friday, February 21st 2025, which permits the company to repurchase $500,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 4.2% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company's leadership believes its shares are undervalued.

Neurocrine Biosciences' top institutional investors include Vanguard Group Inc. (9.89%), Dodge & Cox (5.61%), State Street Corp (4.51%) and JPMorgan Chase & Co. (4.30%). Insiders that own company stock include Neurocrine Biosciences Inc, Kevin Charles Gorman, Kyle Gano, Gary A Lyons, Eric Benevich, William H Rastetter, Darin Lippoldt, Matt Abernethy, Richard F Pops, Stephen A Sherwin, Eiry Roberts, Julie Cooke, Jude Onyia, David W Boyer, Ingrid Delaet, Shalini Sharp, Leslie V Norwalk and George J Morrow.
View institutional ownership trends
.

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neurocrine Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Humana (HUM), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

Last Earnings
7/30/2025
Today
8/28/2025
Next Earnings (Estimated)
10/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:NBIX
CIK
914475
Employees
1,800
Year Founded
1992

Price Target and Rating

High Price Target
$185.00
Low Price Target
$115.00
Potential Upside/Downside
+15.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
21 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.38
Trailing P/E Ratio
40.95
Forward P/E Ratio
32.36
P/E Growth
0.99
Net Income
$341.30 million
Net Margins
13.88%
Pretax Margin
21.00%
Return on Equity
13.22%
Return on Assets
9.39%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.20
Quick Ratio
3.10

Sales & Book Value

Annual Sales
$2.36 billion
Price / Sales
5.83
Cash Flow
$3.42 per share
Price / Cash Flow
40.49
Book Value
$27.17 per share
Price / Book
5.10

Miscellaneous

Outstanding Shares
99,180,000
Free Float
94,421,000
Market Cap
$13.74 billion
Optionable
Optionable
Beta
0.25

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:NBIX) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners